Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSE:002399 Stock Report

Market Cap: CN¥15.2b

Shenzhen Hepalink Pharmaceutical Group Management

Management criteria checks 3/4

Shenzhen Hepalink Pharmaceutical Group's CEO is Yu Shan, appointed in Apr 1998, has a tenure of 27.08 years. total yearly compensation is CN¥2.66M, comprised of 49.4% salary and 50.6% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth CN¥60.72M. The average tenure of the management team and the board of directors is 2.9 years and 14.2 years respectively.

Key information

Yu Shan

Chief executive officer

CN¥2.7m

Total compensation

CEO salary percentage49.36%
CEO tenure27.1yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure14.2yrs

Recent management updates

Recent updates

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Price Is Out Of Tune With Revenues

Mar 27
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Price Is Out Of Tune With Revenues

Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Is Making Moderate Use Of Debt

Feb 19
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Is Making Moderate Use Of Debt

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Business Is Trailing The Industry But Its Shares Aren't

Dec 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Business Is Trailing The Industry But Its Shares Aren't

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Oct 07
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio

Aug 22
Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Jun 12
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

May 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

CEO Compensation Analysis

How has Yu Shan's remuneration changed compared to Shenzhen Hepalink Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

CN¥648m

Dec 31 2024CN¥3mCN¥1m

CN¥647m

Sep 30 2024n/an/a

-CN¥146m

Jun 30 2024n/an/a

-CN¥243m

Mar 31 2024n/an/a

-CN¥695m

Dec 31 2023CN¥3mCN¥1m

-CN¥783m

Sep 30 2023n/an/a

CN¥218m

Jun 30 2023n/an/a

CN¥340m

Mar 31 2023n/an/a

CN¥559m

Jan 01 2023n/an/a

CN¥727m

Sep 30 2022n/an/a

CN¥432m

Jun 30 2022n/an/a

CN¥414m

Mar 31 2022n/an/a

CN¥332m

Jan 01 2022n/an/a

CN¥241m

Sep 30 2021n/an/a

CN¥777m

Jun 30 2021n/an/a

CN¥781m

Mar 31 2021n/an/a

CN¥912m

Dec 31 2020CN¥5mCN¥2m

CN¥1b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥808m

Dec 31 2019CN¥2mCN¥2m

CN¥1b

Compensation vs Market: Yu's total compensation ($USD369.20K) is above average for companies of similar size in the CN market ($USD167.06K).

Compensation vs Earnings: Yu's compensation has been consistent with company performance over the past year.

CEO

Yu Shan (64 yo)

27.1yrs

Tenure

CN¥2,660,000

Compensation

Mr. Yu Shan co-founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in April 1998 and has been its General Manager since April 21, 1998 and serves as its Group Vice President. From August 1982 to Febru...

Leadership Team

NamePositionTenureCompensationOwnership
Li Li
Co-Founder27.1yrsCN¥3.74mno data
Yu Shan
Co-Founder27.1yrsCN¥2.66m0.40%
CN¥ 60.7m
Tan Li
Co-founderno dataCN¥2.46mno data
Ping Zhang
Executive Directorno dataCN¥3.77mno data
Juan Chen
VP of Finance1.8yrsCN¥992.60kno data
Tao Han
Chief Business Officerno datano datano data
Xi Gao
Senior Vice President of Global Supply Chain2.2yrsno datano data
Sze Ting Chan
Joint Company Secretaryno datano datano data
Fengqi Qian
Company Secretary3.6yrsCN¥1.67mno data

2.9yrs

Average Tenure

59yo

Average Age

Experienced Management: 002399's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Li Li
Co-Founder27.1yrsCN¥3.74mno data
Yu Shan
Co-Founder27.1yrsCN¥2.66m0.40%
CN¥ 60.7m
Tan Li
Co-founder27.1yrsCN¥2.46mno data
Ping Zhang
Executive Director2yrsCN¥3.77mno data
Haijun Tang
Supervisor17.4yrsno datano data
Jilan Su
Employee Supervisor17.4yrsno datano data
Zehui Zheng
Chairman of Supervisory Board11yrsno datano data
Chuan Lu
Independent Non-Executive Director5.4yrsCN¥100.00kno data
Israel Vlodavsk
Chairman of Hepalink’s Scientific Advisory Boardno datano datano data
Nathan Karin
Member of Hepalink’s Scientific Advisory Boardno datano datano data
Ming Yi
Independent Non-Executive Director2yrsCN¥100.00kno data
Peng Huang
Independent Non-Executive Director2yrsCN¥100.00kno data

14.2yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 002399's board of directors are seasoned and experienced ( 14.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 18:15
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei TianAJ Securities Co., Ltd
Peng YanChangjiang Securities Co. LTD.
Wai Ming KongDBS Bank Ltd